Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Testosterone Lawsuits Rise to 201 Complaints Alleging Heart Attack, Stroke and Blood Clots from Using Testosterone Products Reports The Oliver Law Group
  • USA - English


News provided by

The Oliver Law Group

Oct 06, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX

To learn about filing a testosterone lawsuit contact the Oliver Law Group P.C. for your free testosterone lawsuit case review by calling toll free 800-939-7878 today or visit www.legalactionnow.com
To learn about filing a testosterone lawsuit contact the Oliver Law Group P.C. for your free testosterone lawsuit case review by calling toll free 800-939-7878 today or visit www.legalactionnow.com

To learn about filing a testosterone lawsuit contact the Oliver Law Group P.C. for your free testosterone lawsuit case review by calling toll free 800-939-7878 today or visit www.legalactionnow.com

Post this

Detroit MI (PRWEB) October 06, 2014 -- As testosterone lawsuit litigation moves into the discovery phase in the U.S. District Court, Northern District of Illinois, the Oliver Law Group P.C. reports that the number of testosterone lawsuit filings have increased 13 percent in the past month. The testosterone complaints have been filed on behalf of men and their survivors who allege that they have suffered heart attacks, blood clots, strokes and deaths as a result of using one or more testosterone replacement therapy products, such as AndroGel, Androderm and Axiron. The federal district court’s master list shows that testosterone complaints rose from 177 as of August 15th, 2014, to 201 as of September 15, 2014. Court documents indicate that the low testosterone complaints all have common allegations and a panel of federal judges in June consolidated the testosterone lawsuits in the Northern Illinois federal court and placed under the supervision of U.S. District Judge Matthew F. Kennelly. (In re: Testosterone Replacement Therapy Product Liability Litigation – MDL No. 2545). The Oliver Law Group P.C. notes that the centralization of the complaints for pretrial proceedings with help the litigation progress more efficiently by avoiding duplicative discovery and inconsistent court rulings.
[jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-September-15-2014.pdf, September 15, 2014]

The request by plaintiffs in the testosterone complaints to consolidate all federally filed testosterone lawsuits was made after the U.S. Food & Drug Administration (FDA) announced that it was investigating the safety and effectiveness of testosterone products. FDA-approved testosterone products are used to treat hypogonadism, which is low testosterone levels in men due to an underlying medical condition. In January, the FDA said it was reassessing testosterone medication after reviewing two studies that linked life-threatening cardiovascular risks to testosterone use. The first study the FDA reviewed was published in the November 2013 Journal of the American Medical Association. This study found that older men who had underlying cardiovascular disease and took low testosterone treatment had a 30 percent increased risk of having a stroke, heart attack or death compared to men who did not take the low testosterone medication. The second study the FDA reviewed was published in the PLOS One Journal on January 29, 2014, found that men over 65 and younger men with a pre-existing heart disease who were prescribed testosterone drugs were at a greater risk of having a heart attack within the first 90 days after taking the medication for the first time.
[fda.gov/Drugs/DrugSafety/ucm383904.htm, January 31, 2014]
[plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0085805, January 29, 2014]
[jama.jamanetwork.com/article.aspx?articleid=1764051, November 6, 2013]

As part of its investigation, the FDA scheduled a two-day meeting of its Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss two controversial issues surrounding testosterone use. According to background information provided online by the FDA prior to its meetings on September 17-18 in Hyattsville, Maryland, the FDA wants its advisory panels to identify the appropriate patient population to take testosterone replacement therapy and discuss the potential cardiovascular risks associated with low testosterone products, including heart attacks, strokes, blood clots and death.
[fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM412536.pdf, August 22, 2014]

In addition to the FDA, Health Canada announced its concerns over testosterone replacement drugs. In July, the Canadian government’s health department instructed manufacturers of testosterone products including Andriol, Androderm, AndroGel, Axiron, Delatestryl, Depo-Testosterone, Testim and their equivalent generics to update their drug labels to reflect the risk of heart attack, stroke, blood clots in the lungs or legs, and increased or irregular heart rate with the use of testosterone products. Health Canada also issued a safety alert to patients and healthcare providers on the potential for testosterone replacement therapy to cause life-threatening heart and blood vessel problems.
[ healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/40587a-eng.php, July 15, 2014 ]

Court documents indicate that an AndroGel and Axiron side-effects complaint was recently filed in the U.S. District Court, Northern District of Illinois on behalf of a Colorado man who alleges that use of the low testosterone medication caused him to have a myocardial infarction (Case: 1:14-cv-06795) The lawsuit states that the Colorado resident’s doctor prescribed Axiron in March 2013. In April 2013, the Colorado resident’s urologist changed medication and prescribed AndroGel. According to the testosterone lawsuit, the Colorado man was hospitalized from June 15, 2013 to June 17, 2013 and was diagnosed with a myocardial infarction (heart attack).

The testosterone lawsuit complaint purports that the defendants, AbbVie Inc., and Abbott Laboratories, which manufactures and markets AndroGel; and Eli Lilly and Company, which manufactures and markets Axiron failed to adequately warn consumers and their health care providers about the cardiovascular risks of using their respective testosterone products. The AndroGel and Axiron testosterone complaint contends that had the Colorado resident and his doctors knew about the true risks associated with testosterone medication use, he would not have taken AndroGel and Axiron, and would have been adequately monitored for the side-effects of the testosterone products.

Free Low Testosterone Lawsuit Reviews
The Oliver Law Group P.C. is offering free low testosterone lawsuit reviews to men who allegedly suffered heart attacks, strokes or other cardiovascular events due to testosterone replacement drugs. Free legal evaluations are also being offered to families of men who allegedly died as result of a testosterone-related heart event. To learn more about filing a testosterone therapy lawsuit, please contact our office by calling 800-939-7878 today.

About The Oliver Law Group P.C.
Oliver Law Group P.C. is a different kind of law firm. One that focuses on the needs of the injured first. A compassionate law firm dedicated to fighting for the rights of victims and their families, and doing everything necessary to ensure those rights.

The experience of a large firm. The 1-on-1 dedication of a small firm. A reputation built on trust.
Experience. Dedication. Trust. Oliver Law Group P.C.

If you would like to learn more about filing a testosterone lawsuit, turn to the law firm with the Experience, Dedication, and Trust you deserve. Contact the Oliver Law Group P.C. for your free case review by calling toll free 800-939-7878 today or visit http://www.legalactionnow.com

Alyson Oliver, The Oliver Law Group, http://www.legalactionnow.com, +1 800-939-7878, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.